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Abstract
Drug-resistant tuberculosis (DR-TB) is a global challenge
and a major contributor of death from anti-microbial resistance.
With the main aim to determine factors contributing to treatment
outcomes observed among DR-TB patients in the countries in
Eastern Europe and Central Asia (EECA), a multi-method study
was conducted in: Azerbaijan, Belarus, Romania, Tajikistan and
Ukraine. Both quantitative and qualitative methodologies were
used for data collection and analysis. The quantitative approach-
es included a desk review of documents related to the DR-TB
responses and an analysis of clinical records of DR-TB patients
in selected health facilities of the five countries. Qualitative
methods included in-depth interviews with national TB pro-
gramme (NTP) managers, other healthcare providers and non-
governmental organizations (NGOs) workers, as well as inter-
views and Focus Group Discussions (FGDs) with DR-TB
patients. The desk review of 38 reports identified as the main
challenges to address DR-TB financial and/or management
issues and adverse events of the medicines. The most common
recommendations related to treatment outcome focussed on gen-
eral programme management, treatment regimen composition,
clinical management and social support for the patients. In all
the five countries the NTPs still have a vertical structure. Some
integration into the primary health care system (PHC) already
exists but further involvement of PHC facilities is feasible and
recommended. Interviews with stakeholders indicated that alco-
holism and homelessness and a lack of appropriate response to
these issues remain as major challenges for a sub-set of patients.
Civil society groups, NGOs and communities are substantially
engaged in providing different services to DR-TB patients, espe-
cially in Ukraine, Romania and Tajikistan. Data from clinical
records of 212 patients revealed that independent risk factors for
unfavourable treatment outcome (death, loss to follow-up, fail-
ure) were culture-positivity at two months of treatment, history
of treatment with second-line drugs and homelessness. More
powerful, less toxic and shorter oral treatment regimens as well
as comprehensive patient support are needed to improve treat-
ment outcome of patients with DR-TB. 
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Introduction
Drug-resistant tuberculosis (DR-TB) is a major challenge glob-
ally and in most of the countries in Eastern Europe and Central Asia
(EECA). Nine of the world’s 30 high DR-TB burden countries are
located in the EECA region [1]. The estimated incidence of TB in the
WHO European Region was 28 per 100,000 in 2018 [2] ranging
from 2.7 per 100,000 in Iceland to 116 per 100,000 in Kyrgyzstan
[3]. The prevalence of DR-TB between new and retreatment cases
was 18% and 54%, respectively, whereas the global averages were
3.4% and 18% respectively [2]. A substantial proportion of patients
with DR-TB harbour extensively drug-resistant TB (XDR-TB)
strains of Mycobacterium tuberculosis. Globally, the proportion of
DR-TB put on treatment that had XDR-TB was 7.3%
(11’403/156’071) in 2018; it was 14.8% (7351/49’696) in the
European Region [2], and 18.2% (1444/7926) in Ukraine [4].
Possible contributing factors for the high burden of DR-TB in EECA
include weak health systems (especially after the collapse of the
Soviet Union) [5,6], poorly conceptualised TB programmes [7], lack
of attention/lack of resources, hospitalization, and migration [8].
Importantly, the domestic funding scheme for TB programmes in
place in the majority of countries favours hospital admission with
increased costs and risk of M. tuberculosis transmission [9-12].
The treatment outcomes of patients with DR-TB has been sub-
optimal: a total of 45,955 patients with multi-drug and rifampicin
resistant TB (MDR/RR-TB) were started on second-line treatment
in the EECA region in 2015; only 57% were treated successfully
(cured plus treatment completed). Among the 5482 XDR-TB
cases, only 35% were treated successfully. The corresponding
global figures were 55% and 34%, respectively [1]. Recent evi-
dence shows better results when bedaquiline is included in the reg-
imen and its use is safe [13-15]. Globally research has investigated
the reasons behind the sub-optimal outcomes among DR-TB
patients [16], such as diagnostic delay leading to advanced disease,
severe drug-resistance patterns, drug side effects, socio-economic
and psycho-social conditions hindering good treatment adherence
[17], and migration [18]. However, not much is known on the
determinants of treatment outcomes in the EECA region.
The aim of this study was to determine the factors contributing
to treatment outcomes observed among DR-TB patients in EECA
taking advantage of the support received from the Global Fund for
TB. The impact of provision of a continuum of care for risk groups
and community engagement were also assessed.
Materials and Methods
Five countries were selected for this study (Azerbaijan,
Belarus, Romania, Tajikistan and Ukraine) using a convenience
sampling method. Study teams were composed of one national
expert and one international expert (in Ukraine, there were two
international experts). To ensure consistency, the same internation-
al researcher participated in all five country visits. A total of 21
regions (called oblasts) were visited in the selected countries. In
each country, half of the selected regions had the highest and the
other half the lowest treatment success rates (based on the 2013
cohort). In Azerbaijan and Ukraine, this selection criterion could
not be fully met due to security concerns and due to the small num-
ber of DR-TB patients registered in some regions respectively. 
In all five countries, the same quantitative and qualitative
methodologies were used for data collection and analysis. 
Quantitative approaches
A) A desk review of documents related to the DR-TB responses.
Most documents included in the desk review were reports of
National TB Programme (NTP) reviews and the Green Light
Committee (GLC) missions for the period between 2010 and
2016, provided by the Global Fund and the respective National
TB Programmes. The GLC is a regional mechanism supporting
implementation of quality DR-TB responses by countries. The
document review specifically looked at patient population
groups, main challenges and recommendations related to treat-
ment outcome. 
B) An analysis of clinical records of DR-TB patients in selected
health facilities of the five countries. In each selected region,
one peripheral health facility was selected for the review of the
patient charts. The review of the patient charts was performed
to identify the characteristics of patients with DR-TB and to
create an Excel-based database for establishing potential deter-
minants of treatment outcome. Data extracted include patient-
related items (e.g., age, sex, body mass index - BMI), diagnos-
tic results, disease-related items (e.g., disease location, co-
morbidities), treatment related items (e.g., number of previous
TB treatment episodes, mode of directly observed therapy -
DOT), treatment regimens provided and treatment outcome.
Charts of patients with DR-TB registered in 2013 were select-
ed by asking in each visited health facility the healthcare
providers to randomly select patient charts and present them to
the study team. Descriptive analysis was done using frequency
distributions. Bi-variate analysis and a multivariate logistic
regression analysis were done to determine risk factors for
unfavourable treatment outcomes; in a multivariate model,
alcohol consumption, sex, HIV status and four of the five risk
factors found to be statistically significant in the bi-variate
analysis were included. The excluded risk factor was BMI: it
could not be included because of the many missing values.
Qualitative approaches 
Qualitative methods included:
A) In-depth interviews (IDIs) with providers. The IDIs were con-
ducted with key informants at national and oblast level, with
providers at health facility level and with NGO workers. A
total of 156 in-depth interviews were completed among care
providers (including NGO workers), programme staff and
other stakeholders.
B) Interviews as well as Focus Group Discussions (FGDs) with
DR-TB patients to explore their views about DR-TB and its
treatment. Patient interviews and FGDs were performed at
peripheral health facilities with DR-TB patients using semi-
structured interview/FDG guides. A total of 8 FGDs (4 in
Ukraine, 2 in Belarus, 1 in Romania and 1 in Tajikistan) and 20
patient interviews (4 in Ukraine, 1 in Belarus, 7 in Romania, 3
in Tajikistan and 5 in Azerbaijan) were conducted with DR-TB
patients (4 of them were co-infected with HIV). Most of these
DR-TB patients were still on treatment at the time of the FGD
or interview, respectively. None of the patients with
unfavourable outcome were interviewed. 
A focus during the patient and provider interviews/FGDs was
factors hindering and factors promoting successful completion of
treatment. During IDIs and FGD, notes were taken to capture the
participants’ statements. The interviews and FGDs were conducted
in the local languages, using a question guide. The notes were
translated into English. We used the framework approach for qual-
itative analysis [19]. 
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The findings from the qualitative and quantitative methods were
triangulated when appropriate [20]. All interviewees (including par-
ticipants of FGDs) gave oral consent to be interviewed. Ethical
clearance was obtained from relevant authorities of each country. 
Results
Desk reviews 
Thirty-eight reports were reviewed (13 from Belarus, 11 from
Ukraine, 6 from Romania, 4 from Tajikistan and 4 from Azerbaijan).
Sixteen of the 38 reports were GLC mission reports. Patient popula-
tion groups identified included: prisoners and people living with
HIV, mentioned in a majority of the reports (in 29 and 27 reports,
respectively); homeless people, illicit drug users and migrants, men-
tioned in one third of the reports reviewed (in 13, 13 and 12 reports,
respectively); people struggling with alcohol addiction, mentioned
in only four reports (in 3 reports from Belarus and 1 report from
Ukraine); refugees/internally displaced people, mentioned in three
reports; and people with mental disorders, mentioned in two reports. 
The main challenges mentioned in the reports were of financial
and/or management nature or related to adverse events of the med-
icines, as summarised in Table 1.
The most common recommendations found in the reports that
were related to treatment outcomes referred to general programme
management, regimen composition, clinical management and
social support for the patients (Table 2).
TB services in the five countries:
findings from the interviews with providers
In all five countries the national TB programmes still have a
vertical structure, being implemented separately from other health-
care programmes. Although some integration into the primary
health care system (PHC) already exists, further involvement of
PHC facilities is feasible and recommended. 
In all five countries, the majority of TB and DR-TB patients are
hospitalized at least during the initial phase of treatment and until
smear- and/or culture conversion. The number of “TB hospital beds”
has recently been reduced to liberate financial resources for other
aspects of TB care. However, financing per TB hospital bed occu-
pied still prevails. Ambulatory treatment is being promoted although
the rate and degree of implementation varies by country. 
Interviews with stakeholders in the five countries indicated
that alcoholism and homelessness are major challenges for a sub-
set of patients and that support for such patients needs to be
strengthened. Civil society groups, NGOs and communities are
substantially engaged in providing different services to DR-TB
patients in Ukraine, Romania and Tajikistan; the NGO engage-
ment is less strong in Azerbaijan and Belarus. Details on NGO
involvement in the five countries are summarised below and in
Table 3.
Belarus
Red Cross Belarus provides psychosocial support to TB/DR-
TB patients; it organizes the consultation with the organization’s
psychologist if needed, and offers social assistance (such as help
with administrative procedures, e.g., getting documents). The Red
Cross also helps with transportation, especially for patients who
reside far from the treating sites and provides small monetary
incentives to patients as a reward for treatment adherence. The
focus of the NGO “Defeat TB together”, is advocacy towards the
Ministry of Health to defend the TB patients’ interests. 
Ukraine
There are a few NGOs providing services to TB/DR-TB
patients. The two biggest organizations that are active throughout
the country are the Red Cross of Ukraine and the All-Ukrainian
Network of People living with HIV. The patient organization
‘’Ukraine against TB‘’ has started active work in Kiev, participat-
ing in the development of TB control activities. “Ukraine against
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Table 1. Identified challenges in the reports of the five countries.
Category of challenges (identified in at least 3 reports)        n 
Financial and/or management challenge                                                           11
Programme management                                                                                     10
Side effects of medicines                                                                                      6
Management, other                                                                                                 5
Social support for patient in general                                                                  4
Ancillary drugs (e.g., limited access)                                                                  3
Other challenges                                                                                                      6
Table 2. Most common recommendations related to treatment completion.
Focus of recommendation                                                                          Number of recommendations with this focus
Programme management                                                                                                                                                         43
Design/composition of regimen                                                                                                                                             20
Clinical management                                                                                                                                                                 14
Social support for patient (in general)                                                                                                                                 14
Financial and/or management issue                                                                                                                                      11
Side effects, ancillary drugs                                                                                                                                                    10
Training                                                                                                                                                                                          9
Various other specific support for patients, e.g., food or psychological support                                                       5
Management other than typical programme issues                                                                                                           5
Community-based DOT/care                                                                                                                                                    4
DOT, directly observed therapy. 
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TB” works closely with the NTP, with a focus on ambulatory treat-
ment promotion. The Red Cross in Ukraine supports, through the
Global Fund grant, DR-TB patients during treatment. The treat-
ment adherence support includes enabling support (e.g., trans-
portation tickets and cash payments that patients can use to cover
some of their expenses), food/hygiene sets, and clothes.
Furthermore, a few NGOs provide psychosocial consultation and
social support (e.g., help with missing documents, or getting regis-
tration or application to state benefits). 
Romania
The main role of NGOs in Romania is to support the TB-specific
Multi-Disciplinary Teams (MDTs) approach, implemented in 6
regions. MDTs consist of a social worker, a psychologist and a doc-
tor/pulmonologist. With funding received from foreign aid, the NGO
“Association for Supporting MDR-TB patients” hires social workers
and psychologists dedicated to TB patients. These specialists are
based in the TB department of regional hospitals and collaborate with
TB health providers on case evaluation and risk assessment. Social
workers and psychologists from the MDTs provide face-to-face and
phone-based support. They also provide food or transport vouchers,
as well as administrative support such as establishment of missing
documents and state benefit applications (which are often requests for
medical pensions of TB patients). MDTs also refer patients to have
DOT in dispensaries close to their place of residence. The NGO
involvement in TB treatment and care has led to a form of integrated
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Table 3. Overviews of the NGO activities in reference to TB care in the five countries.
Criteria                                                    Belarus                    Ukraine                   Romania                  Tajikistan                Azerbaijan
Main                                                                           Red Cross                       Red Cross                       Romanian Angel             Coalition “Stop TB        TB Azerbaijan
NGOs/CSOs active in DR-TB identified            Belarus                            of Ukraine                       Appeal Foundation        partnership,                   Coalition, composed
during field visit                                                      Republican public         All-Ukrainian                  Centre for Health         Tajikistan”,                      of several NGOs:
                                                                                   association “Defeat     Network of People       Policies and Services   Youth led-NGO              “Saglamliga
                                                                                   Tuberculosis                  living with HIV                Association of TB          “Young generation        Khidmat”, “Hayat”, 
                                                                                   Together”                        Patient organization     patients                           of Tajikistan”                  “Azerbaijan Red
                                                                                                                              “Ukraine against TB”   The Association for      13 organizations,           Crescent Society”,
                                                                                                                              Other local                     Supporting                      mostly in the field         “Unit of Professional 
                                                                                                                              CSOs                                MDR-TB Patients          of HIV/AIDS.                   TB doctors and
                                                                                                                                                                        ARAS (working with      Two organisations         Pulmonologists”
                                                                                                                                                                        IDUs)                               (“EFEW” and                 and “Veremsiz
                                                                                                                                                                        Salvati Copiii (Save      “Red Tulip”) are           Dunya” NGO
                                                                                                                                                                        the Children)                 active in the prison
                                                                                                                                                                        UNOPA                            sector
                                                                                                                                                                        Romanian Red Cross
Levels of intervention of NGOs/CSOs              Red Cross                      Some have national      Some work done           No national coverage,  Mostly local work by
                                                                                   Belarus has national    coverage                          centrally                          Mostly local work by     CSOs
                                                                                   coverage                         Local CSOs work at      Coverage of several      CSOs
                                                                                   Mostly local                    oblast level or below    regions
                                                                                   work by CSOs                                                           Overall very active
                                                                                                                                                                        NGO work
Type of support                                                       Working with                 Participation in the       Political advocacy          TB and DR-TB care       Food support and
                                                                                   children with TB            development of TB       TB and DR-TB care       including screening      psychosocial
                                                                                   Psychological                  control activities           in an integrated             contacts, TB                   support
                                                                                   rehabilitation                 Promotion of                  response with the        infection control and   Advocacy with public
                                                                                   Social support                ambulatory treatment  national TB                     treatment monitoring  authorities
                                                                                   packages                         Provision of                    programme                    Psychosocial support   Public awareness
                                                                                                                              psychological or            Community-based         to TB patients                raising on TB
                                                                                                                              social support to           support through            Incentive payment
                                                                                                                              TB patients                     peer supporters,           to patients
                                                                                                                                                                        social workers               Support with
                                                                                                                                                                        and psychologists,        transportation
                                                                                                                                                                        Multi-disciplinary          Administrative
                                                                                                                                                                        teams.                             support
                                                                                                                                                                                                                  Research
Provision of DOT                                                    No                                     Yes, home-based          Home-based for            Yes, different                 Not confirmed by data
                                                                                                                              DOT through hired       children, otherwise      models:                            collection evidence
                                                                                                                              nurses                             in ambulatory                 (a) home-based 
                                                                                                                                                                                                                  DOT through trained
                                                                                                                                                                                                                  volunteers,
                                                                                                                                                                                                                  (b) health
                                                                                                                                                                                                                  facility-based DOT
                                                                                                                                                                                                                  through trained
                                                                                                                                                                                                                  health workers
To be continued on next page
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support services for TB patients, which is widely appreciated, by
patients and providers. However, to a certain extent, NGO-led TB
services developed parallel systems to public institutions: the NGO-
supported social workers do not belong to the Ministry of Labour and
Social Affair and have no institutional linkage to the cadre of public
social workers accountable to city halls. Collaboration between the
two cadres of social workers takes place but does not seem systematic
and largely depends on personal initiatives. 
Tajikistan
There are several NGOs involved in TB, TB/HIV and DR-TB
care, ranging from screening contacts, TB infection control to
monitoring of treatment. Some of them provide psychosocial sup-
port to TB patients, provide payments to patients as an incentive to
stay in treatment, help with transportation, and help with getting
documents and other necessary paperwork. However, this work is
not yet countrywide. Financing for their operations is to a large
extent provided through the Global Fund. Some local administra-
tions contribute to a small extent. 
Azerbaijan
There are several NGOs involved in health care, but just two are
active in TB care. The first is an NGO called “Association of profes-
sional unit of TB specialists and Pulmonologists” (APP). They offer
support to the TB patients (mainly food support and psychosocial
support). In order to solve the problem of TB treatment after dis-
charge from prisons, a grant was sought from the Global Fund and
in March 2011, an NGO called ‘Saglamliga Khidmat’ (translated as
Support to Health) launched a project for ex-prisoner TB patients.
This initiative led to a drastic reduction of lost to follow-up after
release to almost zero and the treatment success rate for new sputum
smear-positive drug-susceptible TB patients increased to 88%. 
Findings from the interactions with patients and
providers related to treatment outcome
Factors perceived to promote successful treatment outcome
In FGDs and patient interviews, the commonly mentioned fac-
tors motivating the patients were the desire to survive, a good
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Table 3. Continued from previous page.
Criteria                                                    Belarus                    Ukraine                   Romania                  Tajikistan                Azerbaijan
Target population/beneficiaries                         DR-TB/TB patients        DR/TB/HIV patients      DR/TB patients              TB patients                     DR/TB patients
                                                                                   including children         DR/TB patients              IDU, DR/TB patients     DR-TB patients              DR-TB-affected
                                                                                                                              without HIV                    with HIV                           TB/HIV patients             former prisoners 
Participation in national coordination               No evidence found       Yes,                                   All main NGOs               Yes,                                   NGO Saglamliga
body on TB                                                               during country visit       NGO participation in    represented in the       NGO representation    Khidmat”, civil society
                                                                                                                              national coordination   National Country           in the National               partner for the TB 
                                                                                                                              body, including               Coordination                  Coordination                  Europe Coalition, is a 
                                                                                                                              representatives of        mechanism                     Committee on TB,         member of the CCM
                                                                                                                              key population                                                         AIDS and Malaria
                                                                                                                              (e.g., MSM)
Recipient of GF grant                                            Yes, indirectly                Yes                                    Romanian Angel             Yes, and of funds          Yes
(directly or indirectly)                                                                                                                              Appeal is principal        from other donors
                                                                                                                                                                        recipient; many other
                                                                                                                                                                        NGOs receive funding
                                                                                                                                                                        from GF grant
Overall assessment                                               A small number of        NGOs are well               NGOs are a major         NGOs are well               A small number of
                                                                                   NGOs and CSOs            represented and           driving force in the       represented, active      NGOs provide limited
                                                                                   provide limited social  engaged in the TB         national DR/TB               and frequent fund        social and
                                                                                   and psychological          response in Ukraine,   response in filling         recipients or                  psychological
                                                                                   support                            and provide                    many gaps of the           implementing                 support but they
                                                                                   NGO involvement          complementary             public response            partners of foreign       have formed a
                                                                                   remains rather              services to the NTP      They have fostered       aid donors in the           coalition which is a
                                                                                   marginal in a                   in close cooperation    the development of      field of TB or HIV.         positive development
                                                                                   centrally-controlled,     with health                      an advanced model       The integration of         towards greater
                                                                                   national TB response   providers                        of integrated care for  NGO TB work within    coordinated
                                                                                                                                                                        DR/TB patients              the national                    action from civil
                                                                                                                                                                        The numerous NGO     response                         society in the
                                                                                                                                                                        actors and                       remains rather              field of TB
                                                                                                                                                                        NGO-funded                  limited                             Contacts are
                                                                                                                                                                        services can lead to                                                established with the
                                                                                                                                                                        parallel systems and                                              national response
                                                                                                                                                                        multiple layers of                                                    system but no
                                                                                                                                                                        interventions                                                            systematic or
                                                                                                                                                                        Of all case studies, it is                                         integrated
                                                                                                                                                                        the most effective                                                   collaboration was
                                                                                                                                                                        involvement of NGOs                                             visible
                                                                                                                                                                        in the TB response
ARAS, Romanian Association Against AIDS; CCM, Country Coordinating Mechanism; CSO, Civil society organisation; DR, drug resistant; NGO, non-governmental organisation; DOT, directly observed therapy; GF, Global
Fund; IDU, Injecting drug user; MSM, men who have sex with men; UNOPA, National Union of Organizations of People Affected by HIV/AIDS. 
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patient-provider relationship, family support and food as incentive.
Table 4 presents these findings. 
The patients were specifically asked if receiving psychological
support through a psychologist would be helpful. In four of the eight
FGDs (in Ukraine and Belarus), this was seen as helpful. Roughly
half of the interviewed patients (9/20) saw this as helpful. In
Romania, support seemed strongest (5 of 7 saw it as helpful).
Similarly, the patients were asked if guided patient group discussions
would be helpful. In all except one FGD and in seven of the twenty
patient interviews was this seen as helpful or possibly helpful. A
patient from Romania explained that she would like to provide advice
to patients (as a volunteer), listen to them and share her own experi-
ence. She added that willingness and awareness of patients is crucial.
Among the positive comments of patients regarding group dis-
cussions were: 
• “Yes, mutual peer support is very important through personal
relationships” (Ukraine).
• “Moral support from other patients means a lot and would be
helpful” (Ukraine).
Many of the just mentioned factors were also mentioned by the
various types of providers. Home-based DOT (treatment at home
of patient) was mentioned as a facilitating factor for treatment by
the providers in all five visited countries. Mostly, patients men-
tioned this only indirectly. Linked to this is video-observed treat-
ment (VOT); at the time of the field work of the study, Belarus had
already had positive experience with VOT. And as of October
2019, more than 1000 patients had experienced VOT (Skrahina
2019, personal communication). In Ukraine, a desire for VOT was
expressed.
In general, across the five countries, providers indicated that
they understood the difficult situations patients face and believe
that provision of comprehensive patient support is critical.
However, a few participants tended to blame patients due to lack
of understanding of the behaviour of some patients including those
who are marginalized and those with mental health issues and who
may require a high degree of professionalism and positive attitude
from healthcare providers. 
Approaches that promote successful treatment outcome men-
tioned by the respondents include good management of side
effects, provision of more information about the medicines’ side
effects to the patients, shorter treatment regimens, good patient-
provider relationship, food as incentives, home-based DOT, family
and psychological support, guided patient group discussion and
video-observed therapy.
Factors perceived to discourage patients from
completing treatment
Factors mentioned in FGDs and patient interviews that dis-
courage patients from completing treatment are summarized in
Table 5. 
Similar factors were also mentioned by the various types of
providers. The following were obstacles mentioned by the
providers in at least 4 of the countries visited but not commonly
mentioned by the patients: 
• Patients’ lack of comprehensive information about TB and its
treatment at the start of treatment 
• Stigma attached to TB
• Patients’ economic needs and employment seen as incompati-
ble with treatment
Suggestions were made on how to facilitate successful treat-
ment outcome: giving monthly a small amount of money to the
patient and at the end of treatment a larger amount. Similarly, the
DOT provider can also receive a financial incentive. It was also
stated that more ambulatory treatment would help though some
providers expressed doubt if all patients would be able to manage
ambulatory treatment. 
Review of charts of patients with DR-TB
Description of the patients, including co-morbidities
Charts of 212 patients (77 in Romania, 65 in Ukraine, 30 in
Azerbaijan, 23 in Tajikistan and 17 in Belarus) registered in 2013
in the selected health facilities were reviewed and data were
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Table 4. Factors perceived or mentioned by patients to promote successful treatment outcome.
Factor                                                                                   Mentioned                  Mentioned               Examples
                                                                                               in FGDs*          in patient interviews°
The desire to survive/The knowledge that cure is attainable         BLR, TJK, UKR              AZE, ROM, TJK, UKR            We understand that we need to go for
                                                                                                                                                                                                                  treatment until the end (TJK)
Good patient-provider relationship                                                      BLR, ROM, TJK                       AZE, ROM                     The relationship with the nurses and doctors
                                                                                                                                                                                                                  is good (AZE)
Family support                                                                                                BLR, ROM                       AZE, ROM, TJK                 My father gave great support, without him
                                                                                                                                                                                                                  I would not have survived (TJK)
Food as incentive                                                                                                BLR                                   AZE, TJK                       Patient needs to eat good food – it is also
                                                                                                                                                                                                                  like medicine (AZE)
Concern / love about family, children                                                             UKR                                      ROM                          My concern about my family and children
                                                                                                                                                                                                                  (ROM)
Moral support from co-patients                                                                      BLR                                      ROM                          We as patients morally support each other
                                                                                                                                                                                                                  (BLR)
Good management of side effects/more information on side      BLR, ROM, UKR                            AZE                           There are many side effects; we would like
effects/less side effects                                                                                                                                                                     to have treatment with “good” drugs (BLR)
The hope to go back to work soon                                                             UKR, BLR                                     -                              What motivates is the hope that after the
                                                                                                                                                                                                                  treatment is finished I will find a job (UKR)
*No FGD was done in Azerbaijan; °in Belarus, only one patient interview was done (with a HIV-positive patient): this conversation did not yield any meaningful information; BLR, Belarus; TJK, Tajikistan; UKR, Ukraine;
ROM, Romania; AZE, Azerbaijan. Mentioned in only one country were: i) shorter and more supportive treatment (UKR); ii) ambulatory treatment (UKR); iii) financial incentives (ROM); iv) health staff giving explana-
tions and hope (BLR); v) social support (AZE); vi) religion (UKR); (vii) support from friends (ROM); and viii) being well informed by health staff (ROM). 
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extracted. Most of the 212 patients were male (71%). The median
age was 41 years (range: 11 to 79 years). Seventy five percent of
the patients were unemployed when their TB illness began. The
median bodyweight at baseline was 62 kg; 17% (37/212) had a
bodyweight below 50 kg. Among the 105 patients with information
on height and weight, 18% (n=19) had low BMI (<18.5 kg/m2).
Three patients had extra-pulmonary TB and 209 had pulmonary
TB. Sixty-nine percent of the patients (147/212) had at least one
cavity in their chest radiography and 36% (n=76) had bilateral dis-
ease and at least one cavity. Of the 212 DR-TB patients, 201 (95%)
had records of HIV status; 9.4% (20/212) were HIV-positive. The
proportion of HIV-positive DR-TB cases was high in Ukraine:
24.6% (16 of 65). It was low in Belarus (1 of 17), Romania (2 of
77) and Azerbaijan (1 of 30). None of the 23 patients of Tajikistan
was HIV-positive. Eight percent (16) had diabetes mellitus.
Patient features at the initiation of treatment
At initiation of treatment, 45% (96) had a record of smoking
cigarettes, 30% (64) of regularly consuming alcohol, and 5% (11)
of using illicit drugs. Eleven percent (23) had a history of detention
and 7% (15) homelessness as shown in Table 6. 
Sixty-five percent (137) had a history of at least one previous
TB treatment; among them, 24.1% (33/137) had a treatment out-
come of “lost to follow-up”. Among the 212 patients, 14.6% had
had three or more previous TB treatment episodes and 19.8% had
a history of at least one previous treatment for DR-TB. At baseline,
66.5% (141) had positive smears, 86% (183) positive culture and
57% (120) positive smear and culture results. Xpert MTB/RIF test-
ing was done for 49 patients in three of the countries (none of the
patients in Azerbaijan and Tajikistan had Xpert testing in 2013)
and of these, 45 had RR. 
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Table 5. Factors perceived or mentioned by patients to discourage them from completing treatment.
Factor                                                                                   Mentioned                  Mentioned               Examples
                                                                                               in FGDs*          in patient interviews°
Side effects                                                                                                 BLR, TJK, UKR              AZE, ROM, TJK, UKR            I had suffered hearing loss, but it is better to
                                                                                                                                                                                                                  be deaf then dead (ROM)
The long duration of treatment                                                                  BLR, UKR                        AZE, ROM, TJK                 Hearing that treatment would last for two
                                                                                                                                                                                                                  years was shocking (ROM)
                                                                                                                                                                                                                  Please invent something so that the
                                                                                                                                                                                                                  treatment is not so long! (UKR)
                                                                                                                                                                                                                  I cannot afford to stay out of work, meaning
                                                                                                                                                                                                                  I have no time for treatment
Lack of general support or family support                                                    TJK                                  ROM, TJK                      Nobody cares if you die or live (TJK)
Getting fed up with the daily routine                                                              TJK                                   AZE, UKR                      I feel very tired doing the same thing every
                                                                                                                                                                                                                  day (UKR)
No trust in treatment or healthcare providers                                               -                                      AZE, TJK                       Some do not trust the doctors and think they
                                                                                                                                                                                                                  will not get cured (TJK)
Hospital conditions not good                                                                           UKR                                      ROM                          It would be nice if the hospital facilitated
                                                                                                                                                                                                                  light sport activities such as table tennis or
                                                                                                                                                                                                                  fitness exercises (UKR)
Anxiety, having bad thoughts, shock and disbelief                                      UKR                                       AZE                           I had many bad thoughts (AZE)
*No FGD was done in Azerbaijan; °in Belarus, only one patient interview was done (with a HIV-positive patient): this conversation did not yield any meaningful information. BLR, Belarus; TJK, Tajikistan; UKR, Ukraine;
ROM, Romania; AZE, Azerbaijan. The following factors were mentioned in only one country: i) distance to DOT location, ii) laziness, iii) being far away from home, iv) long stay at hospital, v) stress to be hospitalized,
vi) family not receiving any support, vii) personal freedom restricted, viii) afraid that others will know about the illness.
Table 6. Reported behavioural and social characteristics of the 212 patients.
Behavioural and social feature                                          Categories                       Number                       Percentage
Smoking at baseline                                                                                              Yes                                             96                                             45.3
                                                                                                                                   No                                              80                                             37.7
                                                                                                                  Unclear/not recorded                            36                                             17.0
Alcohol consumption at baseline                                                                       Yes                                             64                                             30.2
                                                                                                                                   No                                             128                                            60.4
                                                                                                                  Unclear/not recorded                            20                                               9.4
Illicit drug use at baseline                                                                                   Yes                                             11                                               5.2
                                                                                                                                   No                                             178                                            84.0
                                                                                                                  Unclear/not recorded                            23                                             10.8
History of detention (imprisonment)                                                              Yes                                             23                                             10.8
                                                                                                                                   No                                             187                                            88.2
                                                                                                                  Unclear/not recorded                             2                                                0.9
Homeless in the past or at baseline                                                                Yes                                             15                                               7.1
                                                                                                                                   No                                             157                                            74.1
                                                                                                                  Unclear/not recorded                            40                                             18.9
No
n-c
om
me
rci
al 
us
e o
nly
[page 158]                                           [Monaldi Archives for Chest Disease 2020; 90:1235]                          
The most common drug resistance patterns at baseline were
resistance to rifampicin and isoniazid (RH) (16%; n=34) and
resistance to RH plus some other first-line drugs (47%; n=100).
Forty-six patients (21.7%) had pre-XDR (21 had MDR-TB with
resistance to a fluoroquinolone and 25 had resistance to an
injectable) and 19 (9%) patients had XDR-TB (Table 7). 
Mode of treatment
Most patients (81%) were hospitalised. Among the 172
patients who were hospitalised, 19% (33) were in hospitals for up
to two months only, 71% (122) were hospitalised for between 2 to
12 months and 8% (14) for more than 12 months. 
For most patients (78.5% of the 195 for whom this was applica-
ble), the place of DOT during ambulatory treatment was at a health
facility; for 10.3% it was at their residence. Fourteen patients (7.2%)
had DOT in other places or had more than one mode of DOT. 
Treatment outcome
After two months of treatment, 22.3% (45/202) were still
smear-positive and 38.2% (73/191) still culture-positive. 
During the time of the patient chart review, 21 patients were
still on treatment and excluded from the cohort analysis for treat-
ment outcome. Among the remaining 191 patients, 58.6% (112)
had favourable treatment outcome (cure or completed treatment)
and 75 (39.3%) had unfavourable treatment outcome: 12.6% (24)
died, 7.3% (14) were lost to follow-up, and 19.4% (37) failed treat-
ment. Furthermore, 2.1% (4) had unclear treatment outcome (two
of them were transferred to prison). 
In Romania, some of the extracted data were from patients
under a Global Fund grant and others were under the NTP without
Global Fund support. While 75% of the patients under the “Global
Fund grant” (15 of 20) had favourable treatment outcome, only
26.3% (15/57) of the patients under NTP (not supported by Global
Fund) had favourable treatment outcome (p=0.0001).
In Azerbaijan, all 30 patients whose patient charts were
reviewed were under Global Fund support; their treatment success
rate was 76.7% (23/30). A similar disaggregation was not available
for patients registered in the other three countries. 
In bivariate analysis, nine potential risk factors for
unfavourable treatment outcome (including HIV status) were
included. BMI <18.5 kg/m2, bilateral lung disease with at least one
cavity, culture-positivity at 2 months of treatment, previous history
of receiving second-line drugs and homelessness in the past or at
baseline were significant risk factors for unfavourable treatment
outcome (p<0.005 for all). Alcohol consumption at baseline was a
marginally significant risk factor (p=0.08). 
In a multivariate analysis, the independent risk factors for
unfavourable treatment outcome were culture-positivity at two
months of treatment, history of treatment with second-line drugs
and homelessness. 
Table 8 presents the findings of the bi- and multivariate analysis. 
Discussion
The main challenges to complete treatment for DR-TB identi-
fied in our study include i) a long regimen with often significant
side effects and emotional distress; ii) long hospitalization result-
ing in separation from family and friends and interruption or termi-
nation of breadwinning activities; iii) lack of support, be it general
support or support from family; and iv) challenging life situations
for a sub-set of patients such as alcoholism and homelessness. In
the global TB community, the awareness is in general high for the
need for additional medical support (and partly also social support)
for some sub-groups, e.g., HIV-positive TB patients and TB
patients with drug addiction. Other sub-groups however, such as
patients suffering from alcoholism and homeless patients, receive
less attention and do not feature prominently in the general dis-
course of the decision makers of TB care. A systematic review pro-
vided evidence that alcohol consumption during treatment is a pre-
dictor for unsuccessful outcome [21]. Alcoholism is a major health
threat in many of the EECA countries [22]. Accordingly, alcohol
treatment interventions should be integrated into routine TB care,
as was done in Tomsk, Russia [23]. Other studies in the EECA
have also identified these or similar challenges. For instance, a
study in Armenia found that in addition to economic reasons, poor
tolerance of and poor response to treatment were the main factors
associated with loss to follow-up [24]. 
Interestingly, the potentially severe economic repercussions
(e.g., loss of work) linked to the long treatment were barely men-
tioned as a challenge in the five countries. This could also be due
to the fact that majority of the patients were unemployed during
initiation of treatment.
Based on the qualitative and quantitative findings, the follow-
ing programmatic changes should be implemented or strengthened
to improve treatment outcome: i) use of shorter regimens; ii)
avoiding unnecessary hospitalization and an emphasis on ambula-
tory, community-based treatment; and iii) comprehensive support
(material and emotional support) for DR-TB patients on treatment,
considering the whole family situation. A recent systematic review
found that material and psychosocial support reduced the propor-
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Table 7. Drug resistance at baseline (212 cases).
Drug resistance patterns (at baseline)                                            Number                      Percentage 
Poly-drug resistance*                                                                                                              3                                             1.4%
Resistance to rifampicin only                                                                                                5                                             2.4%
Resistance to rifampicin and isoniazid (RH)                                                                    34                                           16.0%
Resistance to RH plus at least one other first-line drug                                              100                                         47.2%
Resistance to RH plus at least one fluoroquinolone                                                     21                                            9.9%
Resistance to RH plus at least one injectable                                                                 25                                           11.8%
Extensively drug-resistant tuberculosis                                                                            19                                            9.0%
Other drug resistance or not clear                                                                                      5                                             2.4%
*Resistance to more than one first-line drug other than both isoniazid and rifampicin; RH, rifampicin and isoniazid.
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tion of DR-TB patients with loss to follow-up [25]. Among the 25
studies included in this systematic review, six were were from the
EECA region. Another recent systematic review indicated that
decentralised care improves treatment outcome [26]. 
Regarding the use of short regimens, it is crucial to build up
the evidence base about which short regimens are effective for
various resistance patterns in Europe and beyond [27-29]. For
instance, can DR-TB patients with resistance to fluoroquinolones
be treated with a modified short regimen that replaces the
injectable with bedaquiline? There is an urgent need to support
countries in their efforts to making use of the new TB drugs; a
recent review found that fewer than 20% of persons likely to ben-
efit from either bedaquiline or delamanid have received them
[30]. Fundamental to treatment is that quality assured TB drugs
and ancillary medicines are always available; this is by no means
a given; there have been reports of stock outs of TB drugs in more
than a dozen countries [31]. 
Our findings from the review of the patient charts on determi-
nants of treatment outcome suggest that patients with the following
features need special attention: i) Culture-positive at 2 months; ii)
previous second-line treatment; iii) homelessness in the past or at
baseline. While the first two risk factors call for a stronger regimen
based on drug-susceptibility profile at treatment start, the risk fac-
tor of homelessness calls for special social support and compre-
hensive care. Furthermore, our analysis indicates that having a
BMI below 18.5 kg/m2 is a risk factor for unfavourable treatment
outcome, as also found in China [32]. This indicates the need for
provision of nutritional support for patients with a low BMI. 
The multivariate analysis revealed that being culture-positive
at two months of treatment is a strong risk factor for unfavourable
treatment outcome. Other studies have also described this, for
instance in Latvia [33,34] and Ethiopia [35]. Though some studies
have already looked at sputum culture conversion as a prognostic
marker for end of-treatment outcome [28,36-39], further studies
are warranted on markers for unfavourable treatment outcome and
follow-up of patients on treatment. Strengthening regimens includ-
ing using new and repurposed drugs and oral regimens would be
critical to improve DR-TB treatment outcome. The very recent rec-
ommendations from WHO [40] on the use of all-oral shorter regi-
mens for treatment of DR-TB and XDR-TB (including BPaL for
XDR-TB) and the pipeline of new drugs and regimens [41] are
promising and would contribute to better treatment outcome of
patients with DR-TB including XDR-TB. 
The main limitations of this study were non-random selection of
health facilities and that the views of people with unfavourable DR-
TB outcome were not included due to logistics. However, we believe
that this study provides important information for NTPs and other
stakeholders in their effort to improve the responses to DR-TB. 
In conclusion, more powerful, less toxic and shorter oral treat-
ment regimens as well as comprehensive patient support including
through digital technologies are needed to improve treatment out-
come of patients with DR-TB. 
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